



# About the Genetype Acquisition

A leading personalised disease risk test portfolio

---

14<sup>TH</sup> JANUARY 2025

# Disclaimer

This presentation has been prepared by **Rhythm Biosciences Limited** (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undertakings in this presentation.

This presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. Rhythm makes no warranty or representation (express or implied) as to the accuracy, reliability or completeness of the information contained in this presentation. Specifically, several matters referred to in the presentation remain under investigation and are subject to change or even elimination, depending on further research and investigation. Further, any opinions (including any forward-looking statements) expressed in this presentation are subject to change without notice. Rhythm and its directors, officers, employees, advisers and agents shall have no liability (including liability to any person by reason of negligence or negligent misstatement) for any statements, opinions, information or matters (express or implied) arising out of, contained in or derived from or for any omissions from this presentation, except liability under statute that cannot be excluded.

This presentation, including the information contained in this disclaimer, does not form part of any offer, invitation or recommendation in respect of shares, or an offer, invitation or recommendation to sell, or a solicitation of any offer to buy, shares in the United States, or in any other jurisdiction in which, or to any person to whom, such an offer would be illegal.

This presentation may include forward-looking statements. Forward-looking statements are only predictions and are subject to known and unknown risks, uncertainties and assumptions, many of which are outside the control of Rhythm. Actual values, results or events may be materially different to those expressed or implied in this presentation depending on a range of factors. Given these uncertainties, recipients are cautioned not to place reliance on forward-looking statements. No representation or warranty (express or implied) is made by Rhythm or any of its directors, officers, employees, advisers or agents that any forecasts, projections, intentions, expectations or plans set out in this presentation will be achieved.

# Genetype acquisition by Rhythm



## Overview

- **Rhythm Biosciences** has completed an asset acquisition agreement for the Genetype business assets.
- Business integration is underway with employee, key process and asset transfer targeted for completion in **Q1 CY2025**.

## Acquisition Drivers

- The combined business advances the mission of early detection of cancer providing access to a substantial global market.
- The acquisition accelerates the business' commercial growth, broadens capability and expands the geographical footprint.
- The expanded multiomics capability of genomics and proteomics supports expansion of the Rhythm product portfolio.

## 2025 – Expected Outcomes

- Accelerated sales of the **geneType™** product platform.
- Expansion of the overall oncology product portfolio.

**Note:** Genetype denotes the overall business and related assets whereas **geneType™** denotes the product

# Transaction Summary



**The acquisition of the Genetype business was clearly focussed on future potential.**

- Rhythm acquired the business and assets related to the Genetype business and geneType™ product portfolio.
- Assets included complete IP portfolio, know-how and trade secrets, branding, domain names (including www.genetype.com), US and Australian permits and licences, select supplier contracts, office lease in US, employee contracts for eight Genetype employees, customer contracts and pending compliance with prevailing privacy regulations, historical patient and clinical data.
- Strong overlap between the Rhythm *Clinical Advisory Board* and the Genetic Technologies *Scientific and Medical Advisory Board* provides continuity with Professors Emery and Macrae continuing to support both platforms.
- Purchase price was AUD\$625,000 **less** payment of accumulated employee entitlements and payments for selected strategic partners chosen by Rhythm.
- Acquisition did not include any legal entity and excluded legacy debts associated with those entities.
- Revenue for all customer cases following 24<sup>th</sup> December 2024 will be recognised by Rhythm.

# About Rhythm Biosciences



**Rhythm Biosciences is committed to saving lives through the early detection of cancers using simple and accurate diagnostic technologies**



Developing novel screening solutions for specific cancers via patient friendly blood tests is our primary focus

---

Patent protected; fully characterised technology that can be readily adopted in all laboratories

---

Targeting large global markets heavily supported by public and private health care systems

---

Competitive product design that supplements and potentially improves current standard cancer testing methods used around the globe

---

**ColoSTAT<sup>®</sup>**: A novel product with anticipated commercial launch in 2H CY2025

# About the geneType™ product

## A leading genomic testing portfolio



- The **geneType™** product portfolio is a world-leading personalised predictive test portfolio that uses a unique combination of genomic and clinical information to predict risk of chronic disease development. See [www.genetype.com](http://www.genetype.com) for the full test menu and publications.
- geneType™ empowers individuals and physicians to improve health outcomes of people around the world enabling a new era of personalised medicine.
- The portfolio includes a patented **Multi Risk Test (MRT)** and Hereditary Breast and Ovarian Cancer (HBOC), a comprehensive breast and ovarian cancer test. Currently the HBOC test is only available in the US.
- MRT was launched in 2021 by Genetic Technologies in the US and Australia with 79.5% of tests providing novel health insights previously unknown.<sup>1</sup>
- geneType™ clinical performance has been established and published<sup>2</sup> with two examples being:
  - **Colorectal cancer:** Identifies significant numbers of individuals with risk equivalent to having a 1<sup>st</sup> degree relative with cancer.<sup>3</sup>
  - **Breast cancer:** identification of 4X more at-risk woman compared to traditional models.<sup>4</sup>
- geneType™ is currently protected by **25 granted patents** and 9 pending.
- Commercial traction with medical and payer B2B channels with several key partnerships close to finalisation.





Notes:

1. Based on in-house reported results to end of May 2024 for the geneType MRT 79.5% of patient results demonstrated elevated risk for one or more diseases <https://genetype.com/for-medical-practitioners/the-science/>
2. Gafni et al. PlosOne 2021; Spaeth et al. JCO 2023
3. Spaeth et al. Can Prev Res 2023; Allman et al. Breast Cancer Res Treat 2023
4. Spaeth et al. Can Prev Res 2023; Allman et al. Breast Cancer Res Treat 2023

# Detecting cancer earlier and maintaining wellness

The power of the combination of the Rhythm and Genetype capabilities and portfolio



**A powerful combination enabling:**  
 Support preventative measures to maintain wellness,  
 Increase the likelihood of earlier disease detection,  
 Promote better treatment outcomes for detected disease,  
 Potential use in drug clinical studies for patient stratification,  
 Potential for development as companion diagnostic tests.

**Suitable for 100s millions of individuals/patients globally**

**Example:** geneType™ bowel cancer risk assessment of the general population to help guide usage of ColoSTAT®. Potentially leads to improved screening compliance, earlier disease detection and improved outcomes.

# Multiomics: Proteins and Genes

Rhythm Biosciences now has both a genomic and proteomic platform



Cancer is a complex disease that is typified by continuous change in cellular DNA, RNA (genome) and proteins (proteome).

- The genome and proteome contain non-overlapping information and disease characterisation is based on information at both genomic and proteomic level.
- Disease risk prediction uses genomic assessment combined with clinical and familial history.
- Early disease detection (screening) uses genomic, proteomic or a combination (multiomic) data.
- Having capability in both fields of research and clinical diagnostic capability is an important asset that strengthens the Company.





# Upcoming value inflection points

PRODUCT	ITEM	DESCRIPTION	ESTD. DELIVERY DATE
ColoSTAT®	Alpha Assay Ready	Arrival of Alpha kits for testing	☑
ColoSTAT®	Beta Release Candidate	Beta Kits ready for verification	☑
geneType™	Genetype business integration	Complete integration of Genetype organisation	1H CY25
ColoSTAT®	Kit Validation Ready	Kit Verification completion, production kits ready.	1H CY25
geneType™	geneType™ relaunch	Relaunch and growth acceleration of geneType product portfolio	1H CY25
ColoSTAT®	Commercialisation	ColoSTAT® Partner's In House IVD launch	2H CY25
ColoSTAT® & geneType™	Portfolio expansion	Update on protein and genomic product portfolio expansion	2H CY 25

# Conclusion



## Overview

Rhythm has made a strategically important acquisition that accelerates commercial growth and expands our product portfolio potential.

## Key Investment Highlights

A diversified, commercial stage business with a rich and rapidly maturing product portfolio.

## Growth

Rhythm is now a business that can be measured both on its tremendous potential and actual commercial growth.



For further information:  
[david.atkins@rhythmbio.com](mailto:david.atkins@rhythmbio.com)